Optimizing Medication Treatment of Opioid Use Disorder During COVID-19 (SARS-CoV-2)
- 13 May 2020
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Addiction Medicine
- Vol. 14 (4), e1-e3
- https://doi.org/10.1097/adm.0000000000000678
Abstract
The COVID-19 health crisis joined, rather than supplanted, the opioid crisis as the most acutely pressing threats to US public health. In the setting of COVID-19, opioid use disorder treatment paradigms are being disrupted, including the fact that methadone clinics are scrambling to give “take-home” doses where they would typically not. The rapid transition away from in-person examination, dosing and group therapy in an era of social isolation calls for adjustments to clinical practice, including emphasizing patient-provider communication, favoring new inductees on buprenorphine and leveraging technology to optimize safety of medication treatment.Keywords
This publication has 1 reference indexed in Scilit:
- Methadone in Primary Care — One Small Step for Congress, One Giant Leap for Addiction TreatmentThe New England Journal of Medicine, 2018